Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — 32nd Annual J.P. Morgan Healthcare Conference (January 2014)
26 slides from Halozyme Therapeutics's conference presentation, Jan 13, 2014
Slide 1: The Next Chapter Begins: Creating Value Through Growth
Halozyme Therapeutics, Inc. The Next Chapter Begins: Creating Value Through Growth 32nd Annual J. P. Morgan Healthcare Conference January 2014 Helen Torley, M.B., CH. B., M.R.C.P. President and Chief Executive Officer EXHIBIT 99.2
Slide 2: Forward-Looking Statements
2 <#> All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include future product development and regulatory events and goal
Slide 3: Halozyme: Creating Value Through Growth
3 <#> Approval and Launch of Proprietary Products Maximize Royalty Revenue from Existing Collaborations Expand and Deepen Partnerships Halozyme: Creating Value Through Growth Time
Slide 4: Our Science: Delivering A Broad Global Portfolio
4 <#> Marketed Under Review Late Stage Early Stage PROPRIE T A R Y US P A RTNE R E D EU/RoW EU/RoW Global EU US PEGPH20 Pancreatic Cancer Global Rights Hylenex® Diabetes Global Rights HTI-501 Cellulite Global Rights Our Science: Delivering A Broad Global Portfolio
Slide 5: Approval and Launch of Proprietary Products
5 <#> Approval and Launch of Proprietary Products Halozyme: Creating Value Through Growth Time
Slide 6: Hylenex: First Proprietary Product
6 <#> • Approved by FDA to increase dispersion and absorption of other injected drugs and fluids • Commercial infrastructure established in U.S. • Established as the #1 prescribed hyaluronidase1 Hylenex®: First Proprietary Product NOTE: 1) IMS monthly hyaluronidase market share (May 2013 – September
Slide 7: PEGPH20 In Pancreatic Cancer – Significant Unmet Medical Need
7 <#> 45.2 54.6 US EU Pancreatic Cancer – Annual Incidence (in 000s)1 NOTE: 1) National Cancer Institute, Pancreatic Action Network, Cancer.gov, US SEER, company and analyst reports. • Over 100K newly diagnosed patients annually • Frequently not diagnosed until late stage • Despite recent advances,
Slide 8: PEGPH20: Novel Approach For Solid Tumor Treatment
8 <#> n CH2 CH2 OCH2 O CH3 N H O CH2 CH2 OO CH2 CH3 N H O n CH2 CH2 OO CH2 CH3 N O H n n CH2 CH2 OCH2 O CH3 N H O CH2 CH2 OO CH2 CH3 N O H n • Pegylated form of Halozyme’s rHuPH20 that depletes Hyaluronan (HA) • High HA levels in tumors creates a more favorable microenvironment for tumor growth PEGP
Slide 9: PEGPH20 Synergizes Cancer Therapies Increasing Survival (In Vivo)
9 <#> Gem PEG Gem+PEG Median Survival (days) 55 65 95+ * • PEGPH20 depletes the HA in the tumor matrix resulting in: Direct inhibition of tumor growth Synergy with other therapeutics resulting in increased drug perfusion - Chemotherapeutics and mAbs • Activity demonstrated in multiple animal can
Slide 10: Phase 1b Patients With Tumor Cell Associated HA+ Had Longer PFS and OS
10 <#> 0 50 100 150 200 250 300 0.0 0.2 0.4 0.6 0.8 1.0 ITT=154 days HA high HA low 219 days 108 days Time (days) P ro p o rt io n o f P F S 0 90 18 7 6 450 540 0.0 0.2 0.4 0.6 0.8 1.0 ITT =200 days HA high HA low 529 days 174 days Time (days) P ro p o rt io n o f S u rv iv a l N Median OS (days) Ce
Slide 11: Enrolling Phase 2 Pancreatic Cancer Clinical Trials
11 <#> PEGPH20 + Abraxane + Gemcitabine until disease progression Abraxane + Gemcitabine until disease progression Stage IV Metastatic PDA N=126 KPS 70-100 Biopsy Tissue 1:1 PEGPH20 + mFOLFIRINOX until disease progression mFOLFIRINOX until disease progression Stage IV Metastatic PDA N=140 ECOG 0-1 B
Slide 12: Solid Tumor Opportunity: New Study Planned In 4Q14
12 <#> % of Solid Tumor Cases with HA+ Staining Source: Gut 2013;62:112–120 - Jacobetz. Results are based on human tissue microassays. 0% 20% 40% 60% 80% 100% Pancreatic (Composite) Breast Prostate Bladder Stomach Pleura Lung (NSCLC) Colon Ongoing Solid Tumor Studies Solid Tumor Opportunity: New Stu
Slide 13: Opportunity To Improve Results In Insulin Pump Users
13 <#> • Pump use growing in both Type 1 and 2 diabetes ~500,000 users in the US • Continuous Subcutaneous Insulin Infusion (CSII) via pump2: Improves glycemic control Decreases glucose variability May reduce hypoglycemia risk Improves quality of life • Unmet need remains to further improv
Slide 14: Hylenex Pre-Treatment Of The Insulin Pump Infusion Site
14 <#> Accelerating Insulin Absorption: Goal = Improved Glycemic Control 110 110 122 64 0 20 40 60 80 100 120 140 Early (0-3 hours) Late (3-5 hours) Usual CSII Hylenex Mean Area Below 70 mg/dL (min*mg/dL) +11% (p=.75) -42% (p=.046) Less Hypoglycemia 200 180 160 140 120 100 0 60 120 180 240 300 Time
Slide 15: CONSISTENT 1 Trial Design
15 <#> Evaluating Hylenex® + rapid analog insulins for Type 1 diabetic adults on insulin pump therapy I. Primary endpoint at 4 months: A1C II. Secondary endpoints at 4 months include: Rates of hypoglycemia Post-prandial glucose excursions Safety CSII + Hylenex® CSII Control CSII + Hylenex® A
Slide 16: Hylenex (Insulin Pumps): Key Steps To Commercialization
16 <#> Top-line CONSISTENT 1 Data - (1Q2014) CONSISTENT 1 Data Submitted to Major Medical Conference - (2014) Late-Stage Clinical Trials Compatibility Demonstrated with Multiple Tubing Sets Pre- Administration Solutions sNDA Under Review for High Capacity Fill and Finish – (2014) Manufacturing Scale
Slide 17: HTI-501 (rHuCAT-L): A Potential Treatment For Cellulite
17 <#> • Recombinant Human Cathepsin-L Digests collagen Focal control of collagen degradation • Current Status and Upcoming Activities Phase 1 completed Doses well tolerated Phase 2 results expected 1Q2014 Strategic evaluation underway HTI-501 (rHuCAT-L): A Potential Treatment For Cellul
Slide 18: Maximize Royalty Revenue from Existing Collaborations
18 <#> Maximize Royalty Revenue from Existing Collaborations Expand and Deepen Partnerships Halozyme: Creating Value Through Growth Time
Slide 19: Significant Acceleration In Partnerships And Programs
19 <#> Significant Acceleration In Partnerships And Programs 2013 2 2 4 10 Approved Programs Filed Programs Announced Programs Undisclosed Targets/Programs 5 Partnerships 18 Targets/Programs
Slide 20: Partnered Programs Drive Short- And Long-Term Revenue
20 <#> Royalties from top-line sales plus milestones UP TO 6 ADDITIONAL TARGETS • 4 Exclusive targets for Primary & Specialty Care (First disclosed target is PCSK-9) UP TO 2 ADDITIONAL TARGETS Partnered Programs Drive Short- And Long-Term Revenue
Slide 21: Roche Subcutaneous Product Sales Illustration
21 <#> *This information presented below is not intended to be a sales projection and is for illustrative purposes only. Roche has not provided any guidance on the commercial potential for these products* NOTE: 1) Financial information obtained from Roche investor update (January 30, 2013). Amounts
Slide 22: Current Status Of Commercial Collaborations
22 <#> Key Highlights - Herceptin SC Formulation (HER2+ Breast Cancer) • Approved and launched in EU (September 2013) • 92% preference by patients1 • Demonstrated to reduce HCP and patient time2 • Filed in multiple countries (x-US/x-Japan) Key Highlights - MabThera SC Formulation (Non-Hodgkin’s Lymp
Slide 23: Halozyme: Creating Value Through Growth
23 <#> • Support partnered filings, approvals & launches Herceptin SC MabThera SC HyQvia PCSK9 Maximize Royalty Revenue from Existing Collaborations • Advance subcutaneous programs with Pfizer and Roche • Sign new partnerships Expand and Deepen Partnerships • Advance clinical trials for PEGPH20
Slide 24: Poised For A Pivotal Year In 2014 – Major Upcoming Milestones
24 <#> NOTE: 1) Source: Roche Investor Meeting – American Society of Hematology , pg. 45 (December 9th, 2013). Poised For A Pivotal Year In 2014 – Major Upcoming Milestones HyQvia PEGPH20 (Pancreatic Cancer) MabThera1 Complete Study 202 Enrollment 2H2014 Initiate Patient Enrollment in New Solid Tumo
Slide 25: Halozyme: Creating Value Through Growth
25 <#> Approval and Launch of Proprietary Products Maximize Royalty Revenue from Existing Collaborations Expand and Deepen Partnerships Halozyme: Creating Value Through Growth Time
Slide 26: Slide 26
Halozyme Therapeutics — 32nd Annual J.P. Morgan Healthcare Conference (January 2014) on 6ix